Expect significant share price decline on the Phase III failure. Monitor root cause analysis results and any updates on efti program viability. The company's cash runway and cost cuts provide some buffer, but the lead program's failure introduces substantial uncertainty.
Price Chart
Executive Summary
Immutep reported discontinuation of its lead TACTI-004 Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer following an IDMC futility analysis. The efti arm underperformed the control arm, prompting a wind-down and root cause analysis that may impact the broader efti program. The company has a cash position of A$110.6 million but faces a US$10 million payment obligation to partner Dr. Reddy's, and has initiated cost reductions including headcount cuts.
Key Facts
- TACTI-004 Phase III trial discontinued after IDMC interim futility analysis showed efti arm underperformed control arm in 1L NSCLC
- Root cause analysis ongoing; implications for efti development program under review
- Immutep must pay US$10 million to Dr. Reddy's by June 2026 due to trial discontinuation
- Cash, cash equivalents, and term deposits total A$110.6 million as of March 31, 2026
- Cash used in R&D activities was A$11.8 million in Q3 FY26
- Cost reduction measures initiated, including targeted headcount reduction
- IMP761 Phase I trial progressing to multiple ascending dose phase; data expected at EULAR June 2026
- EFTISARC-NEO Phase II met primary endpoint; FDA orphan drug designation received
- Net cash from operating activities was A$13.5 million in Q3 FY26, driven by Dr. Reddy's upfront payment
Financial Impact
Material – TACTI-004 discontinuation erodes pipeline value; US$10 million cash outflow to Dr. Reddy's due in June 2026; cash position of A$110.6 million provides runway into H1 CY2028; no revenue or EPS reported
Risk Factors
- Root cause analysis may reveal broader issues with efti, leading to program discontinuation
- Potential need for additional financing if cash burn accelerates or milestones are missed
- Reliance on Dr. Reddy's partnership; further obligations or changes in collaboration terms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-201355 |
| Document: d70756d6k.htm | 0001193125-26-201355 |
| Document: 0001193125-26-201355-index-headers.html | 0001193125-26-201355 |
| Document: 0001193125-26-201355-index.html | 0001193125-26-201355 |
| Document: 0001193125-26-201355.txt | 0001193125-26-201355 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 1, 2026 25w ago | 6-K | $0.0500 $0.0500 | · 0.00% | ▲ +3.07% | $0.0200 (+60.00%) |
Apr 1, 2026 29w ago | 3 | $0.0400 $0.0500 | ▲ +25.00% | ▲ +11.62% | $0.0200 (−50.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers